<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1995-4484-2017-58-67</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2340</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROGRESS IN RHEUMATOLOGY IN THE XXI CENTURY</subject></subj-group></article-categories><title-group><article-title>Боль и воспаление. Часть 2. Анальгетический потенциал противовоспалительных препаратов</article-title><trans-title-group xml:lang="en"><trans-title>PAIN AND INFLAMMATION. PART 2. THE ANALGESIC POTENTIAL OF ANTI-INFLAMMATORY DRUGS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>зав. лабораторией гастроэнтерологических проблем при ревматических заболеваниях ФГБНУ НИИР им. В.А. Насоновой, канд. мед. наук</p><p>115522 Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><email xlink:type="simple">aekarateev@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>Д. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>D. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>врио директора ФГБНУ НИИР им. В.А. Насоновой, докт. мед. наук</p><p>115522 Москва, Каширское шоссе, 34А</p></bio><bio xml:lang="en"><p>34A, Kashirskoe Shosse, Moscow 115522</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Давыдов</surname><given-names>О. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Davydov</surname><given-names>O. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ведущий научный сотрудник Научно-практического психоневрологического центра им. З.П. Соловьева Департамента здравоохранения г. Москвы, канд. мед. наук</p><p>115419 Москва, ул. Донская, 43</p></bio><bio xml:lang="en"><p>43, Donskaya St., Moscow 115419</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБНУ «Научно- исследовательский институт ревматологии им. В.А. Насоновой»<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">Научно-практический психоневрологический центр им. З.П.  Соловьева Департамента здравоохранения г. Москвы<country>Россия</country></aff><aff xml:lang="en">Z.P. Solovyev Research and Practical Center of Psychoneurology<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>08</day><month>03</month><year>2017</year></pub-date><volume>55</volume><issue>1</issue><fpage>58</fpage><lpage>67</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каратеев А.Е., Каратеев Д.Е., Давыдов О.С., 2017</copyright-statement><copyright-year>2017</copyright-year><copyright-holder xml:lang="ru">Каратеев А.Е., Каратеев Д.Е., Давыдов О.С.</copyright-holder><copyright-holder xml:lang="en">Karateev A.E., Karateev D.E., Davydov O.S.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2340">https://rsp.mediar-press.net/rsp/article/view/2340</self-uri><abstract><p>Воспалительная реакция и развитие боли – взаимозависимые процессы. Воспаление, сопровождающееся гиперпродукцией провоспалительных цитокинов и медиаторов, не только вызывает боль, но и является основной причиной ее хронизации. Поэтому главным направлением анальгетической терапии следует считать использование противовоспалительных препаратов. Во второй части обзора обсуждается анальгетический потенциал различных фармакологических групп, обладающих противовоспалительным действием, – нестероидных противовоспалительных препаратов, глюкокортикоидов, генно- инженерных биологических препаратов, метотрексата, медленно действующих противовоспалительных средств («хондропротекторов»), а также ряда перспективных и экспериментальных средств, таких как ингибиторы фактора роста нервов. Приводятся данные основных клинических исследований, в которых оценивалось обезболивающее действие этих препаратов при различных заболеваниях и патологических состояниях.</p></abstract><trans-abstract xml:lang="en"><p>An inflammatory response and the development of pain are interdependent processes. Inflammation accompanied by the overproduction of proinflammatory cytokines and mediators not only causes pain, but is also the main cause of its chronicity. Therefore, the use of anti-inflammatory drugs should be considered to be the mainstay of analgesic therapy. Part 2 of the review discusses the analgesic potential of various pharmacological groups that have an anti-inflammatory effect: nonsteroidal anti-inflammatory drugs, glucocorticoids, biological agents, methotrexate, slow-acting antiinflammatory drugs (chondroprotectors), as well as a number of promising and experimental agents, such as nerve growth factor inhibitors. It provides data from major clinical trials that have evaluated the analgesic effect of these drugs in various diseases and pathological conditions.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>боль</kwd><kwd>воспаление</kwd><kwd>парацетамол</kwd><kwd>нестероидные противовоспалительные препараты</kwd><kwd>глюкокортикоиды</kwd><kwd>метотрексат</kwd><kwd>генно-инженерные биологические препараты</kwd><kwd>ингибиторы фактора роста нервов.</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pain</kwd><kwd>inflammation</kwd><kwd>paracetamol</kwd><kwd>nonsteroidal anti-inflammatory drugs</kwd><kwd>glucocorticoids</kwd><kwd>methotrexate</kwd><kwd>biological agents</kwd><kwd>nerve growth factor inhibitors</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Противовоспалительная терапия ревматических болезней. Москва: М- СИТИ; 1996. 345 с. [Nasonov EL. Protivovospalitel’naya terapiya revmaticheskikh boleznei [Antiinflammatory therapy of rheumatic diseases]. Moscow: M-SITI; 1996. 345 p.].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Противовоспалительная терапия ревматических болезней. Москва: М- СИТИ; 1996. 345 с. [Nasonov EL. Protivovospalitel’naya terapiya revmaticheskikh boleznei [Antiinflammatory therapy of rheumatic diseases]. Moscow: M-SITI; 1996. 345 p.].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rainsford K. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. doi: 10.1007/1-4020-5688-5_1</mixed-citation><mixed-citation xml:lang="en">Rainsford K. Anti-inflammatory drugs in the 21st century. Subcell Biochem. 2007;42:3-27. doi: 10.1007/1-4020-5688-5_1</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Clauw DJ. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015 Feb;29(1):6-19. doi: 10.1016/j.berh.2015.04.024. Epub 2015 May 23.</mixed-citation><mixed-citation xml:lang="en">Clauw DJ. Diagnosing and treating chronic musculoskeletal pain based on the underlying mechanism(s). Best Pract Res Clin Rheumatol. 2015 Feb;29(1):6-19. doi: 10.1016/j.berh.2015.04.024. Epub 2015 May 23.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ennis ZN, Dideriksen D, Vaegter HB, et al. Acetaminophen for chronic pain: A systematic review on efficacy. Basic Clin Pharmacol Toxicol. 2016 Mar;118(3):184-9. doi: 10.1111/bcpt.12527. Epub 2015 Dec 28.</mixed-citation><mixed-citation xml:lang="en">Ennis ZN, Dideriksen D, Vaegter HB, et al. Acetaminophen for chronic pain: A systematic review on efficacy. Basic Clin Pharmacol Toxicol. 2016 Mar;118(3):184-9. doi: 10.1111/bcpt.12527. Epub 2015 Dec 28.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7. doi: 10.1016/j.plefa.2004.10.005</mixed-citation><mixed-citation xml:lang="en">Botting R, Ayoub SS. COX-3 and the mechanism of action of paracetamol/acetaminophen. Prostaglandins Leukot Essent Fatty Acids. 2005 Feb;72(2):85-7. doi: 10.1016/j.plefa.2004.10.005</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Graham GG, Davies MJ, Day RO, et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013 Jun;21(3):201-32. doi: 10.1007/s10787-013-0172-x. Epub 2013 May 30.</mixed-citation><mixed-citation xml:lang="en">Graham GG, Davies MJ, Day RO, et al. The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology. 2013 Jun;21(3):201-32. doi: 10.1007/s10787-013-0172-x. Epub 2013 May 30.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Machado G, Maher C, Ferreira P, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350:h1225. doi: 10.1136/bmj.h1225</mixed-citation><mixed-citation xml:lang="en">Machado G, Maher C, Ferreira P, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015 Mar 31;350:h1225. doi: 10.1136/bmj.h1225</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti- inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi: 10.2147/JPR.S75160. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Brune K, Patrignani P. New insights into the use of currently available non-steroidal anti- inflammatory drugs. J Pain Res. 2015 Feb 20;8:105-18. doi: 10.2147/JPR.S75160. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Насонов ЕЛ, Яхно НН и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология. 2015;9(1):4-23 [Karateev AE, Nasonov EL, Yakhno NN, et al. Clinical guidelines «Rational use of nonsteroidal anti- inflammatory drugs (NSAIDs) in clinical practice». Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2015;9(1):4-23 (In Russ.)]. doi: 10.14412/1996-7012-2015-1-4-23</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000</mixed-citation><mixed-citation xml:lang="en">McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011 Dec 24;71(18):2457-89. doi: 10.2165/11208240-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Collantes E, Curtis S, Lee K, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10. doi: 10.1186/1471-2296-3-10</mixed-citation><mixed-citation xml:lang="en">Collantes E, Curtis S, Lee K, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam Pract. 2002;3:10. doi: 10.1186/1471-2296-3-10</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Tarp S, Bartels EM, Bliddal H, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012 Nov;64(11):3511-21. doi: 10.1002/art.34644</mixed-citation><mixed-citation xml:lang="en">Tarp S, Bartels EM, Bliddal H, et al. Effect of nonsteroidal antiinflammatory drugs on the C-reactive protein level in rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 2012 Nov;64(11):3511-21. doi: 10.1002/art.34644</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi: 10.1002/14651858.CD010952.pub2</mixed-citation><mixed-citation xml:lang="en">Kroon FP, van der Burg LR, Ramiro S, et al. Non-steroidal antiinflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. 2015 Jul 17;(7):CD010952. doi: 10.1002/14651858.CD010952.pub2</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford). 2010 Mar;49(3):536-41. doi: 10.1093/rheumatology/kep393. Epub 2009 Dec 22.</mixed-citation><mixed-citation xml:lang="en">Benhamou M, Gossec L, Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford). 2010 Mar;49(3):536-41. doi: 10.1093/rheumatology/kep393. Epub 2009 Dec 22.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2</mixed-citation><mixed-citation xml:lang="en">Van Durme CM, Wechalekar MD, Buchbinder R, et al. Nonsteroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev. 2014 Sep 16;(9):CD010120. doi: 10.1002/14651858.CD010120.pub2</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140</mixed-citation><mixed-citation xml:lang="en">Janssens HJ, Janssen M, van de Lisdonk EH, et al. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008 May 31;371(9627):1854-60. doi: 10.1016/S0140</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Zweers M, de Boer T, van Roon J, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13(5):239. doi: 10.1186/ar3437</mixed-citation><mixed-citation xml:lang="en">Zweers M, de Boer T, van Roon J, et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13(5):239. doi: 10.1186/ar3437</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mehta V, Johnston A, Cheung R, et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther. 2008 Mar;83(3):430-5. doi: 10.1038/sj.clpt.6100304. Epub 2007 Aug 8.</mixed-citation><mixed-citation xml:lang="en">Mehta V, Johnston A, Cheung R, et al. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system. Clin Pharmacol Ther. 2008 Mar;83(3):430-5. doi: 10.1038/sj.clpt.6100304. Epub 2007 Aug 8.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Nemeth CL, Glasper ER, Harrell CS, et al. Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. PLoS One. 2014 Oct 1;9(10):e108399. doi: 10.1371/journal.pone.0108399. eCollection 2014.</mixed-citation><mixed-citation xml:lang="en">Nemeth CL, Glasper ER, Harrell CS, et al. Meloxicam blocks neuroinflammation, but not depressive-like behaviors, in HIV-1 transgenic female rats. PLoS One. 2014 Oct 1;9(10):e108399. doi: 10.1371/journal.pone.0108399. eCollection 2014.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Redondo-Castro E, Navarro X. Chronic ibuprofen administration reduces neuropathic pain but does not exert neuroprotection after spinal cord injury in adult rats. Exp Neurol. 2014 Feb;252:95-103. doi: 10.1016/j.expneurol.2013.11.008. Epub 2013 Nov 15.</mixed-citation><mixed-citation xml:lang="en">Redondo-Castro E, Navarro X. Chronic ibuprofen administration reduces neuropathic pain but does not exert neuroprotection after spinal cord injury in adult rats. Exp Neurol. 2014 Feb;252:95-103. doi: 10.1016/j.expneurol.2013.11.008. Epub 2013 Nov 15.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenach JC, Curry R, Rauck R, et al. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology. 2010 May;112(5):1225-33. doi: 10.1097/ALN.0b013e3181d94dc0</mixed-citation><mixed-citation xml:lang="en">Eisenach JC, Curry R, Rauck R, et al. Role of spinal cyclooxygenase in human postoperative and chronic pain. Anesthesiology. 2010 May;112(5):1225-33. doi: 10.1097/ALN.0b013e3181d94dc0</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Goldstein JL, Cryer B. Gastrointestinal injury associated with NSAID use: a case study and review of risk factors and preventative strategies. Drug Healthc Patient Saf. 2015 Jan 22;7:31-41. doi: 10.2147/DHPS.S71976. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi: 10.18433/J3VW2F</mixed-citation><mixed-citation xml:lang="en">Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-47. doi: 10.18433/J3VW2F</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effects. Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S2. doi: 10.1186/ar4686</mixed-citation><mixed-citation xml:lang="en">Van der Goes MC, Jacobs JW, Bijlsma JW. The value of glucocorticoid co-therapy in different rheumatic diseases – positive and adverse effects. Arthritis Res Ther. 2014 Nov 13;16 Suppl 2:S2. doi: 10.1186/ar4686</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3):238- 50 [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(3):238-50 (In Russ.)]. doi: 10.14412/1995-4484-2015-238-250</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место глюкокортикоидов. Научно-практическая ревматология. 2015;53(3):238- 50 [Nasonov EL. New guidelines for the management of rheumatoid arthritis (EULAR, 2013): The place of glucocorticoids. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(3):238-50 (In Russ.)]. doi: 10.14412/1995-4484-2015-238-250</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13. doi: 10.1016/j.mce.2010.04.005. Epub 2010 Apr 14.</mixed-citation><mixed-citation xml:lang="en">Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011 Mar 15;335(1):2-13. doi: 10.1016/j.mce.2010.04.005. Epub 2010 Apr 14.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.</mixed-citation><mixed-citation xml:lang="en">Gotzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Cochrane Database Syst Rev. 2004;(3):CD000189.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman BW, Esses D, Solorzano C, et al. A randomized placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. Spine (Phila Pa 1976). 2008 Aug 15;33(18):E624-9. doi: 10.1097/BRS.0b013e3181822711</mixed-citation><mixed-citation xml:lang="en">Friedman BW, Esses D, Solorzano C, et al. A randomized placebo-controlled trial of single-dose IM corticosteroid for radicular low back pain. Spine (Phila Pa 1976). 2008 Aug 15;33(18):E624-9. doi: 10.1097/BRS.0b013e3181822711</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Abou-Raya A, Abou-Raya S, Khadrawi T, Helmii M. Effect of low-dose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis: a randomized placebo-controlled trial. J Rheumatol. 2014 Jan;41(1):53-9. doi: 10.3899/jrheum.130199. Epub 2013 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Abou-Raya A, Abou-Raya S, Khadrawi T, Helmii M. Effect of low-dose oral prednisolone on symptoms and systemic inflammation in older adults with moderate to severe knee osteoarthritis: a randomized placebo-controlled trial. J Rheumatol. 2014 Jan;41(1):53-9. doi: 10.3899/jrheum.130199. Epub 2013 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Hameed F, Ihm J. Injectable medications for osteoarthritis. PM R. 2012;4(5 Suppl):75-81. doi: 10.1016/j.pmrj.2012.02.010</mixed-citation><mixed-citation xml:lang="en">Hameed F, Ihm J. Injectable medications for osteoarthritis. PM R. 2012;4(5 Suppl):75-81. doi: 10.1016/j.pmrj.2012.02.010</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Habib G, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol. 2010;29(4):347-56. doi: 10.1007/s10067-009-1357-y</mixed-citation><mixed-citation xml:lang="en">Habib G, Saliba W, Nashashibi M. Local effects of intra-articular corticosteroids. Clin Rheumatol. 2010;29(4):347-56. doi: 10.1007/s10067-009-1357-y</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140- 6736(10)61160-9. Epub 2010 Oct 21.</mixed-citation><mixed-citation xml:lang="en">Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140- 6736(10)61160-9. Epub 2010 Oct 21.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.</mixed-citation><mixed-citation xml:lang="en">McAlindon TE, Bannuru RR, Sullivan MC, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014 Mar;22(3):363-88. doi: 10.1016/j.joca.2014.01.003. Epub 2014 Jan 24.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical Guidelines]. 2nd ed. Moscow: GEOTARMedia; 2010].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Ревматология: Клинические рекомендации. 2-е изд. Москва: ГЭОТАР-Медиа; 2010 [Nasonov EL, editor. Revmatologiya: Klinicheskie rekomendatsii [Rheumatology: Clinical Guidelines]. 2nd ed. Moscow: GEOTARMedia; 2010].</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi: 10.1016/j.ejpain.2006.02.013.Epub 2006 May 8.</mixed-citation><mixed-citation xml:lang="en">Bjordal J, Klovning A, Ljunggren A, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: A meta-analysis of randomised placebo-controlled trials. Eur J Pain. 2007 Feb;11(2):125-38. doi: 10.1016/j.ejpain.2006.02.013.Epub 2006 May 8.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">McCabe PS, Maricar N, Parkes MJ, et al. The efficacy of intraarticular steroids in hip osteoarthritis: A systematic review. Osteoarthritis Cartilage. 2016 Apr 30. pii: S1063- 4584(16)30056-5. doi: 10.1016/j.joca.2016.04.018. [Epub ahead of print].</mixed-citation><mixed-citation xml:lang="en">McCabe PS, Maricar N, Parkes MJ, et al. The efficacy of intraarticular steroids in hip osteoarthritis: A systematic review. Osteoarthritis Cartilage. 2016 Apr 30. pii: S1063- 4584(16)30056-5. doi: 10.1016/j.joca.2016.04.018. [Epub ahead of print].</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Jü ni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015 Oct 22;10:CD005328. doi: 10.1002/14651858.CD005328.pub3</mixed-citation><mixed-citation xml:lang="en">Jü ni P, Hari R, Rutjes AW, et al. Intra-articular corticosteroid for knee osteoarthritis. Cochrane Database Syst Rev. 2015 Oct 22;10:CD005328. doi: 10.1002/14651858.CD005328.pub3</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Farooq M, Devitt A. Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons. Ir J Med Sci. 2005;174(1):26-32. doi: 10.1007/BF03168515</mixed-citation><mixed-citation xml:lang="en">Farooq M, Devitt A. Perceived efficacy and risks of infection following intra-articular injections: a survey of orthopaedic surgeons. Ir J Med Sci. 2005;174(1):26-32. doi: 10.1007/BF03168515</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Charalambous C, Tryfonidis M, Sadiq S, et al. Septic arthritis following intraarticular glucocorticoid injection of the knee – a survey of current practice regarding antiseptic technique used during intra-articular glucocorticoid injection of the knee. Clin Rheumatol. 2003;22:386-90. doi: 10.1007/s10067-003-0757-7</mixed-citation><mixed-citation xml:lang="en">Charalambous C, Tryfonidis M, Sadiq S, et al. Septic arthritis following intraarticular glucocorticoid injection of the knee – a survey of current practice regarding antiseptic technique used during intra-articular glucocorticoid injection of the knee. Clin Rheumatol. 2003;22:386-90. doi: 10.1007/s10067-003-0757-7</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and nondiabetic patients. Joint Bone Spine. 2007 Oct;74(5):472-6. doi: 10.1016/j.jbspin.2006.10.009. Epub 2007 Jul 6.</mixed-citation><mixed-citation xml:lang="en">Younes M, Neffati F, Touzi M, et al. Systemic effects of epidural and intra-articular glucocorticoid injections in diabetic and nondiabetic patients. Joint Bone Spine. 2007 Oct;74(5):472-6. doi: 10.1016/j.jbspin.2006.10.009. Epub 2007 Jul 6.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intraarticular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014 May;93(5):372-8. doi: 10.1097/PHM.0000000000000001</mixed-citation><mixed-citation xml:lang="en">Moon HJ, Choi KH, Lee SI, et al. Changes in blood glucose and cortisol levels after epidural or shoulder intraarticular glucocorticoid injections in diabetic or nondiabetic patients. Am J Phys Med Rehabil. 2014 May;93(5):372-8. doi: 10.1097/PHM.0000000000000001</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Chou R, Hashimoto R, Friedly J, et al. Pain management injection therapies for low back pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.</mixed-citation><mixed-citation xml:lang="en">Chou R, Hashimoto R, Friedly J, et al. Pain management injection therapies for low back pain [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Mar. AHRQ Technology Assessments.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Pinto RZ, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med. 2012 Dec 18;157(12):865-77. doi: 10.7326/0003-4819-157-12-201212180-00564</mixed-citation><mixed-citation xml:lang="en">Pinto RZ, Maher CG, Ferreira ML, et al. Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis. Ann Intern Med. 2012 Dec 18;157(12):865-77. doi: 10.7326/0003-4819-157-12-201212180-00564</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Staal JB, de Bie RA, de Vet HC, et al. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2009 Jan 1;34(1):49-59. doi: 10.1097/BRS.0b013e3181909558</mixed-citation><mixed-citation xml:lang="en">Staal JB, de Bie RA, de Vet HC, et al. Injection therapy for subacute and chronic low back pain: an updated Cochrane review. Spine (Phila Pa 1976). 2009 Jan 1;34(1):49-59. doi: 10.1097/BRS.0b013e3181909558</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Ter Meulena B, Weinsteina H, Ostelob R, Koehlerd P. The epidural treatment of sciatica: its origin and evolution. Eur Neurol. 2016;75:58-64. doi: 10.1159/000443729</mixed-citation><mixed-citation xml:lang="en">Ter Meulena B, Weinsteina H, Ostelob R, Koehlerd P. The epidural treatment of sciatica: its origin and evolution. Eur Neurol. 2016;75:58-64. doi: 10.1159/000443729</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Pountos I, Panteli M, Walters G, et al. Safety of epidural corticosteroid injections. Drugs R D. 2016 Mar;16(1):19-34. doi: 10.1007/s40268-015-0119-3</mixed-citation><mixed-citation xml:lang="en">Pountos I, Panteli M, Walters G, et al. Safety of epidural corticosteroid injections. Drugs R D. 2016 Mar;16(1):19-34. doi: 10.1007/s40268-015-0119-3</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): The role of methotrexate. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26 (In Russ.)]. doi: 10.14412/1995- 4484-2014-8-26</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, Каратеев ДЕ, Чичасова НВ. Новые рекомендации по лечению ревматоидного артрита (EULAR, 2013): место метотрексата. Научно-практическая ревматология. 2014;52(1):8-26 [Nasonov EL, Karateev DE, Chichasova NV. New recommendations for the management of rheumatoid arthritis (EULAR, 2013): The role of methotrexate. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):8-26 (In Russ.)]. doi: 10.14412/1995- 4484-2014-8-26</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484- 2015-421-433</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):421-33 [Nasonov EL. Methotrexate in rheumatoid arthritis – 2015: New facts and ideas. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(4):421-33 (In Russ.)]. doi: 10.14412/1995-4484- 2015-421-433</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12-9. doi: 10.2133/dmpk.DMPK-13-RV-119. Epub 2013 Nov 26.</mixed-citation><mixed-citation xml:lang="en">Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. Drug Metab Pharmacokinet. 2014;29(1):12-9. doi: 10.2133/dmpk.DMPK-13-RV-119. Epub 2013 Nov 26.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10;(6):CD000957. doi: 10.1002/14651858.CD000957.pub2</mixed-citation><mixed-citation xml:lang="en">Lopez-Olivo MA, Siddhanamatha HR, Shea B, et al. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014 Jun 10;(6):CD000957. doi: 10.1002/14651858.CD000957.pub2</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. Semin Arthritis Rheum. 2016 Jun;45(6):656-62. doi: 10.1016/j.semarthrit.2015.11.004. Epub 2015 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Li D, Yang Z, Kang P, Xie X. Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis. Semin Arthritis Rheum. 2016 Jun;45(6):656-62. doi: 10.1016/j.semarthrit.2015.11.004. Epub 2015 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Kalunian KC. Current advances in therapies for osteoarthritis. Curr Opin Rheumatol. 2016 May;28(3):246-50. doi: 10.1097/BOR.0000000000000273</mixed-citation><mixed-citation xml:lang="en">Kalunian KC. Current advances in therapies for osteoarthritis. Curr Opin Rheumatol. 2016 May;28(3):246-50. doi: 10.1097/BOR.0000000000000273</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Wenham C, Grainger AJ, Hensor EM, et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford). 2013 May;52(5):888-92. doi: 10.1093/rheumatology/kes386. Epub 2013 Jan 7.</mixed-citation><mixed-citation xml:lang="en">Wenham C, Grainger AJ, Hensor EM, et al. Methotrexate for pain relief in knee osteoarthritis: an open-label study. Rheumatology (Oxford). 2013 May;52(5):888-92. doi: 10.1093/rheumatology/kes386. Epub 2013 Jan 7.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Kingsbury SR, Tharmanathan P, Arden NK, et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase III trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8</mixed-citation><mixed-citation xml:lang="en">Kingsbury SR, Tharmanathan P, Arden NK, et al. Pain reduction with oral methotrexate in knee osteoarthritis, a pragmatic phase III trial of treatment effectiveness (PROMOTE): study protocol for a randomized controlled trial. Trials. 2015 Mar 4;16:77. doi: 10.1186/s13063-015-0602-8</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ. Прогресс ревматологии в начале XXI века. Современная ревматология. 2014;8(3):4-8 [Nasonov EL. Progress in rheumatology in the early 21st century. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(3):4-8 (In Russ.)]. doi: 10.14412/1996-7012-2014-3-4-8</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ. Прогресс ревматологии в начале XXI века. Современная ревматология. 2014;8(3):4-8 [Nasonov EL. Progress in rheumatology in the early 21st century. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2014;8(3):4-8 (In Russ.)]. doi: 10.14412/1996-7012-2014-3-4-8</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 с. [Nasonov EL, editor. Gennoinzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA- PRESS; 2013. 549 p.].</mixed-citation><mixed-citation xml:lang="en">Насонов ЕЛ, редактор. Генно-инженерные биологические препараты в лечении ревматоидного артрита. Москва: ИМА-ПРЕСС; 2013. 549 с. [Nasonov EL, editor. Gennoinzhenernye biologicheskie preparaty v lechenii revmatoidnogo artrita [Genetically engineered biological agents in the treatment of rheumatoid arthritis]. Moscow: IMA- PRESS; 2013. 549 p.].</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 3;12:102. doi: 10.1186/1477-7525-12-102</mixed-citation><mixed-citation xml:lang="en">Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a systematic review and network meta-analysis. Health Qual Life Outcomes. 2014 Jul 3;12:102. doi: 10.1186/1477-7525-12-102</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009 Mar 15;61(3):344-52. doi: 10.1002/art.24096</mixed-citation><mixed-citation xml:lang="en">Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2009 Mar 15;61(3):344-52. doi: 10.1002/art.24096</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Pimentel D, El Abd O, Benyamin R, et al. Anti-tumor necrosis factor antagonists in the treatment of low back pain and radiculopathy: a systematic review and meta-analysis. Pain Physician. 2014 Jan-Feb;17(1):E27-44.</mixed-citation><mixed-citation xml:lang="en">Pimentel D, El Abd O, Benyamin R, et al. Anti-tumor necrosis factor antagonists in the treatment of low back pain and radiculopathy: a systematic review and meta-analysis. Pain Physician. 2014 Jan-Feb;17(1):E27-44.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002</mixed-citation><mixed-citation xml:lang="en">Miller CG, Guermazi A, Roemer F. The current status of imaging in anti-NGF clinical trials. Osteoarthritis Cartilage. 2015 Jan;23 Suppl 1:S3-7. doi: 10.1016/j.joca.2014.09.002</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014 Nov;41(11):2249-59. doi: 10.3899/jrheum.131294. Epub 2014 Oct 1.</mixed-citation><mixed-citation xml:lang="en">Ekman EF, Gimbel JS, Bello AE, et al. Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J Rheumatol. 2014 Nov;41(11):2249-59. doi: 10.3899/jrheum.131294. Epub 2014 Oct 1.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placeboand oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013 Sep;154(9):1603- 12. doi: 10.1016/j.pain.2013.04.035. Epub 2013 Apr 22.</mixed-citation><mixed-citation xml:lang="en">Spierings EL, Fidelholtz J, Wolfram G, et al. A phase III placeboand oxycodone-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain. 2013 Sep;154(9):1603- 12. doi: 10.1016/j.pain.2013.04.035. Epub 2013 Apr 22.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Kan SL, Li Y, Ning GZ, et al. Tanezumab for patients with osteoarthritis of the knee: A meta-analysis. PLoS One. 2016 Jun 13;11(6):e0157105. doi: 10.1371/journal.pone.0157105. eCollection 2016.</mixed-citation><mixed-citation xml:lang="en">Kan SL, Li Y, Ning GZ, et al. Tanezumab for patients with osteoarthritis of the knee: A meta-analysis. PLoS One. 2016 Jun 13;11(6):e0157105. doi: 10.1371/journal.pone.0157105. eCollection 2016.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: A systematic review and a meta-analysis. Pain Physician. 2014;17:45-60.</mixed-citation><mixed-citation xml:lang="en">Leite VF, Buehler AM, El Abd O, et al. Anti-nerve growth factor in the treatment of low back pain and radiculopathy: A systematic review and a meta-analysis. Pain Physician. 2014;17:45-60.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Алексеева ЛИ. Препараты замедленного действия в лечении остеоартроза. Русский медицинский журнал. 2012;(7):389-94 [Alekseeva LI. Slow-acting drugs in the treatment of osteoarthritis. Russkii Meditsinskii Zhurnal. 2012;(7):389-94 (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Алексеева ЛИ. Препараты замедленного действия в лечении остеоартроза. Русский медицинский журнал. 2012;(7):389-94 [Alekseeva LI. Slow-acting drugs in the treatment of osteoarthritis. Russkii Meditsinskii Zhurnal. 2012;(7):389-94 (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition proinflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB. 2007;21(6):702-7.</mixed-citation><mixed-citation xml:lang="en">Au R, Au A, Rashmir-Raven A, Frondoza C. Inhibition proinflammatory gene expression in chondrocytes, monocytes, and fibroblasts by combination of avocado soybean unsaponiables, glucosamine and chondroitin sulfate. FASEB. 2007;21(6):702-7.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi: 10.1002/14651858.cd002946.pub2</mixed-citation><mixed-citation xml:lang="en">Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi: 10.1002/14651858.cd002946.pub2</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90. doi: 10.7326/0003-4819-146-8- 200704170-00009</mixed-citation><mixed-citation xml:lang="en">Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8):580-90. doi: 10.7326/0003-4819-146-8- 200704170-00009</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117. doi: 10.1002/14651858.cd005117.pub2</mixed-citation><mixed-citation xml:lang="en">Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117. doi: 10.1002/14651858.cd005117.pub2</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408. doi: 10.1016/j.joca.2007.10.003</mixed-citation><mixed-citation xml:lang="en">Christensen R, Bartels E, Astrup A, Bliddal H. Symptomatic efficacy of avocado-soybean unsaponifiables (ASU) in osteoarthritis (OA) patients: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage. 2008;16(4):399-408. doi: 10.1016/j.joca.2007.10.003</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. EULAR; 2013, SAT0419.</mixed-citation><mixed-citation xml:lang="en">Singh G, Alekseeva L, Alexeev V, Triadafilopoulos G. Glucosamin-chondroitin sulfate reduces pain, disability and NSAID consumption in patients with chronic low back pain: a large, community-based, pilot, open prospective observational study. EULAR; 2013, SAT0419.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно- практическая ревматология. 2015;53(2):169-74 [Karateev AE, Alekseeva LI. Estimation of diacerein tolerability in real clinical practice: Results of the RACADA (Retrospective Assessment of Clinical Aspects of using Diaflex in osteoArthritis). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):169-74 (In Russ.)]. doi: 10.14412/1995-4484-2015-169-174</mixed-citation><mixed-citation xml:lang="en">Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно- практическая ревматология. 2015;53(2):169-74 [Karateev AE, Alekseeva LI. Estimation of diacerein tolerability in real clinical practice: Results of the RACADA (Retrospective Assessment of Clinical Aspects of using Diaflex in osteoArthritis). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(2):169-74 (In Russ.)]. doi: 10.14412/1995-4484-2015-169-174</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008 Jan;10(1):43-8. doi: 10.1007/s11926-008-0008-7</mixed-citation><mixed-citation xml:lang="en">Kulkarni SK, Singh VP. Licofelone: the answer to unmet needs in osteoarthritis therapy? Curr Rheumatol Rep. 2008 Jan;10(1):43-8. doi: 10.1007/s11926-008-0008-7</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872</mixed-citation><mixed-citation xml:lang="en">Bertolini A, Ottani A, Sandrini M. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res. 2001 Dec;44(6):437-50. doi: 10.1006/phrs.2001.0872</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5- lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009 Jun;68(6):938-47. doi: 10.1136/ard.2008.088732. Epub 2008 Jul 23.</mixed-citation><mixed-citation xml:lang="en">Raynauld JP, Martel-Pelletier J, Bias P, et al. Protective effects of licofelone, a 5- lipoxygenase and cyclo-oxygenase inhibitor, versus naproxen on cartilage loss in knee osteoarthritis: a first multicentre clinical trial using quantitative MRI. Ann Rheum Dis. 2009 Jun;68(6):938-47. doi: 10.1136/ard.2008.088732. Epub 2008 Jul 23.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Kawaguchi A, Sugimoto K, Fujimura A. Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity. Life Sci. 2001 Jan 26;68(10):1181-90. doi: 10.1016/S0024-3205(00)01028-6</mixed-citation><mixed-citation xml:lang="en">Kawaguchi A, Sugimoto K, Fujimura A. Preventive effect of platelet-activating factor antagonist, Y-24180, against cyclosporine-induced acute nephrotoxicity. Life Sci. 2001 Jan 26;68(10):1181-90. doi: 10.1016/S0024-3205(00)01028-6</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004 Apr;309(1):404-13. doi: 10.1124/jpet.103.061754. Epub 2004 Jan 13.</mixed-citation><mixed-citation xml:lang="en">Thurmond RL, Desai PJ, Dunford PJ, et al. A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties. J Pharmacol Exp Ther. 2004 Apr;309(1):404-13. doi: 10.1124/jpet.103.061754. Epub 2004 Jan 13.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Cowden JM, Yu F, Banie H, et al. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis. 2014;73(3):600-8. doi: 10.1136/annrheumdis-2013-203832</mixed-citation><mixed-citation xml:lang="en">Cowden JM, Yu F, Banie H, et al. The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritis. Ann Rheum Dis. 2014;73(3):600-8. doi: 10.1136/annrheumdis-2013-203832</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.</mixed-citation><mixed-citation xml:lang="en">Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533-52. doi: 10.1146/annurev-pharmtox-010814-124701. Epub 2014 Oct 8.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Gang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013 April 5;8(10):938-47. doi: 10.3969/j.issn.1673-5374.2013.10.009</mixed-citation><mixed-citation xml:lang="en">Gang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013 April 5;8(10):938-47. doi: 10.3969/j.issn.1673-5374.2013.10.009</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Bigal ME, Walter S, Rapoport AM Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591</mixed-citation><mixed-citation xml:lang="en">Bigal ME, Walter S, Rapoport AM Therapeutic antibodies against CGRP or its receptor. Br J Clin Pharmacol. 2015 Jun;79(6):886-95. doi: 10.1111/bcp.12591</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">O'Byrne PM. Asthma treatment: antileukotriene drugs. Can Respir J. 1998 Jul-Aug;5 Suppl A:64A-70A.</mixed-citation><mixed-citation xml:lang="en">O'Byrne PM. Asthma treatment: antileukotriene drugs. Can Respir J. 1998 Jul-Aug;5 Suppl A:64A-70A.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Cingi C, Muluk N, Ipci K, Sahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7</mixed-citation><mixed-citation xml:lang="en">Cingi C, Muluk N, Ipci K, Sahin E. Antileukotrienes in upper airway inflammatory diseases. Curr Allergy Asthma Rep. 2015 Nov;15(11):64. doi: 10.1007/s11882-015-0564-7</mixed-citation></citation-alternatives></ref><ref id="cit84"><label>84</label><citation-alternatives><mixed-citation xml:lang="ru">Deeks ED. Icatibant. Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000</mixed-citation><mixed-citation xml:lang="en">Deeks ED. Icatibant. Drugs. 2010;70(1):73-81. doi: 10.2165/11204500-000000000-00000</mixed-citation></citation-alternatives></ref><ref id="cit85"><label>85</label><citation-alternatives><mixed-citation xml:lang="ru">Tricco AC, Soobiah C, Blondal E, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015 Jun 18;13:142. doi: 10.1186/s12916-015-0379-3</mixed-citation><mixed-citation xml:lang="en">Tricco AC, Soobiah C, Blondal E, et al. Comparative safety of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015 Jun 18;13:142. doi: 10.1186/s12916-015-0379-3</mixed-citation></citation-alternatives></ref><ref id="cit86"><label>86</label><citation-alternatives><mixed-citation xml:lang="ru">Liu M, Zhang H, Du BX, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015 May;94(19):e762. doi: 10.1097/MD.0000000000000762</mixed-citation><mixed-citation xml:lang="en">Liu M, Zhang H, Du BX, et al. Neurokinin-1 receptor antagonists in preventing postoperative nausea and vomiting: a systematic review and meta-analysis. Medicine (Baltimore). 2015 May;94(19):e762. doi: 10.1097/MD.0000000000000762</mixed-citation></citation-alternatives></ref><ref id="cit87"><label>87</label><citation-alternatives><mixed-citation xml:lang="ru">Ogawa S, Awaga Y, Takashima M, et al. Knee osteoarthritis pain following medial meniscectomy in the nonhuman primate. Osteoarthritis Cartilage. 2016 Jul;24(7):1190-9. doi: 10.1016/j.joca.2016.02.006. Epub 2016 Mar 2.</mixed-citation><mixed-citation xml:lang="en">Ogawa S, Awaga Y, Takashima M, et al. Knee osteoarthritis pain following medial meniscectomy in the nonhuman primate. Osteoarthritis Cartilage. 2016 Jul;24(7):1190-9. doi: 10.1016/j.joca.2016.02.006. Epub 2016 Mar 2.</mixed-citation></citation-alternatives></ref><ref id="cit88"><label>88</label><citation-alternatives><mixed-citation xml:lang="ru">Iyer JP, Srivastava PK, Dev R, et al. Prostaglandin E(2) synthase inhibition as a therapeutic target. Expert Opin Ther Targets. 2009 Jul;13(7):849-65. doi: 10.1517/14728220903018932</mixed-citation><mixed-citation xml:lang="en">Iyer JP, Srivastava PK, Dev R, et al. Prostaglandin E(2) synthase inhibition as a therapeutic target. Expert Opin Ther Targets. 2009 Jul;13(7):849-65. doi: 10.1517/14728220903018932</mixed-citation></citation-alternatives></ref><ref id="cit89"><label>89</label><citation-alternatives><mixed-citation xml:lang="ru">Mbalaviele G, Pauley AM, Shaffer AF, et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.</mixed-citation><mixed-citation xml:lang="en">Mbalaviele G, Pauley AM, Shaffer AF, et al. Distinction of microsomal prostaglandin E synthase-1 (mPGES-1) inhibition from cyclooxygenase-2 inhibition in cells using a novel, selective mPGES-1 inhibitor. Biochem Pharmacol. 2010 May 15;79(10):1445-54. doi: 10.1016/j.bcp.2010.01.003. Epub 2010 Jan 11.</mixed-citation></citation-alternatives></ref><ref id="cit90"><label>90</label><citation-alternatives><mixed-citation xml:lang="ru">Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. doi: 10.1021/jm401431x. Epub 2013 Dec 4.</mixed-citation><mixed-citation xml:lang="en">Ganesh T. Prostanoid receptor EP2 as a therapeutic target. J Med Chem. 2014 Jun 12;57(11):4454-65. doi: 10.1021/jm401431x. Epub 2013 Dec 4.</mixed-citation></citation-alternatives></ref><ref id="cit91"><label>91</label><citation-alternatives><mixed-citation xml:lang="ru">Sugita R, Kuwabara H, Kubota K, et al. Simultaneous inhibition of PGE2 and PGI2 signals is necessary to suppress hyperalgesia in rat inflammatory pain models. Mediators Inflamm. 2016;2016:9847840. doi: 10.1155/2016/9847840. Epub 2016 Jul 13.</mixed-citation><mixed-citation xml:lang="en">Sugita R, Kuwabara H, Kubota K, et al. Simultaneous inhibition of PGE2 and PGI2 signals is necessary to suppress hyperalgesia in rat inflammatory pain models. Mediators Inflamm. 2016;2016:9847840. doi: 10.1155/2016/9847840. Epub 2016 Jul 13.</mixed-citation></citation-alternatives></ref><ref id="cit92"><label>92</label><citation-alternatives><mixed-citation xml:lang="ru">Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin Immunol. 2015 May;27(3):149-60. doi: 10.1016/j.smim.2015.03.014. Epub 2015 Apr 22.</mixed-citation><mixed-citation xml:lang="en">Headland SE, Norling LV. The resolution of inflammation: Principles and challenges. Semin Immunol. 2015 May;27(3):149-60. doi: 10.1016/j.smim.2015.03.014. Epub 2015 Apr 22.</mixed-citation></citation-alternatives></ref><ref id="cit93"><label>93</label><citation-alternatives><mixed-citation xml:lang="ru">Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015 Apr;1851(4):397-413. doi: 10.1016/j.bbalip.2014.08.006. Epub 2014 Aug 17.</mixed-citation><mixed-citation xml:lang="en">Serhan CN, Dalli J, Colas RA, et al. Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. Biochim Biophys Acta. 2015 Apr;1851(4):397-413. doi: 10.1016/j.bbalip.2014.08.006. Epub 2014 Aug 17.</mixed-citation></citation-alternatives></ref><ref id="cit94"><label>94</label><citation-alternatives><mixed-citation xml:lang="ru">Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm.2015.12.037. Epub 2015 Dec 17.</mixed-citation><mixed-citation xml:lang="en">Cholkar K, Gilger BC, Mitra AK. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016 Feb 10;498(1-2):326-34. doi: 10.1016/j.ijpharm.2015.12.037. Epub 2015 Dec 17.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
